TY - JOUR
T1 - A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3
AU - Schepers, Dorien
AU - Tortora, Giada
AU - Morisaki, Hiroko
AU - MacCarrick, Gretchen
AU - Lindsay, Mark
AU - Liang, David
AU - Mehta, Sarju G
AU - Hague, Jennifer
AU - Verhagen, Judith
AU - van de Laar, Ingrid
AU - Wessels, Marja
AU - Detisch, Yvonne
AU - van Haelst, Mieke
AU - Baas, Annette
AU - Lichtenbelt, Klaske
AU - Braun, Kees
AU - van der Linde, Denise
AU - Roos-Hesselink, Jolien
AU - McGillivray, George
AU - Meester, Josephina
AU - Maystadt, Isabelle
AU - Coucke, Paul
AU - El-Khoury, Elie
AU - Parkash, Sandhya
AU - Diness, Birgitte
AU - Risom, Lotte
AU - Scurr, Ingrid
AU - Hilhorst-Hofstee, Yvonne
AU - Morisaki, Takayuki
AU - Richer, Julie
AU - Désir, Julie
AU - Kempers, Marlies
AU - Rideout, Andrea L
AU - Horne, Gabrielle
AU - Bennett, Chris
AU - Rahikkala, Elisa
AU - Vandeweyer, Geert
AU - Alaerts, Maaike
AU - Verstraeten, Aline
AU - Dietz, Hal
AU - Van Laer, Lut
AU - Loeys, Bart
N1 - © 2018 The Authors. Human Mutation published by Wiley Periodicals, Inc.
PY - 2018/5
Y1 - 2018/5
N2 - The Loeys-Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present with aortic aneurysms and arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate. Initially, mutations in transforming growth factor-β (TGF-β) receptors (TGFBR1 and TGFBR2) were described to cause LDS, hereby leading to impaired TGF-β signaling. More recently, TGF-β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF-β pathway, SMAD2 and SMAD3, were shown to be involved in LDS. This emphasizes the role of disturbed TGF-β signaling in LDS pathogenesis. Since most literature so far has focused on TGFBR1/2, we provide a comprehensive review on the known and some novel TGFB2/3 and SMAD2/3 mutations. For TGFB2 and SMAD3, the clinical manifestations, both of the patients previously described in the literature and our newly reported patients, are summarized in detail. This clearly indicates that LDS concerns a disorder with a broad phenotypical spectrum that is still emerging as more patients will be identified. All mutations described here are present in the corresponding Leiden Open Variant Database.
AB - The Loeys-Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present with aortic aneurysms and arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate. Initially, mutations in transforming growth factor-β (TGF-β) receptors (TGFBR1 and TGFBR2) were described to cause LDS, hereby leading to impaired TGF-β signaling. More recently, TGF-β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF-β pathway, SMAD2 and SMAD3, were shown to be involved in LDS. This emphasizes the role of disturbed TGF-β signaling in LDS pathogenesis. Since most literature so far has focused on TGFBR1/2, we provide a comprehensive review on the known and some novel TGFB2/3 and SMAD2/3 mutations. For TGFB2 and SMAD3, the clinical manifestations, both of the patients previously described in the literature and our newly reported patients, are summarized in detail. This clearly indicates that LDS concerns a disorder with a broad phenotypical spectrum that is still emerging as more patients will be identified. All mutations described here are present in the corresponding Leiden Open Variant Database.
KW - Animals
KW - Disease Models, Animal
KW - Genetic Association Studies
KW - Humans
KW - Loeys-Dietz Syndrome/diagnosis
KW - Mice
KW - Mutation/genetics
KW - Signal Transduction/genetics
KW - Smad2 Protein/genetics
KW - Smad3 Protein/genetics
KW - Transforming Growth Factor beta2/genetics
KW - Transforming Growth Factor beta3/genetics
U2 - https://doi.org/10.1002/humu.23407
DO - https://doi.org/10.1002/humu.23407
M3 - Article
C2 - 29392890
SN - 1059-7794
VL - 39
SP - 621
EP - 634
JO - Human mutation
JF - Human mutation
IS - 5
ER -